Page last updated: 2024-08-07 16:51:35
Adenosine kinase
An adenosine kinase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P55263]
Synonyms
AK;
EC 2.7.1.20;
Adenosine 5'-phosphotransferase
Research
Bioassay Publications (21)
| Timeframe | Studies on this Protein(%) | All Drugs % |
|---|
| pre-1990 | 1 (4.76) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 14 (66.67) | 29.6817 |
| 2010's | 5 (23.81) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Compounds (221)
Drugs with Inhibition Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| abt 702 | Homo sapiens (human) | IC50 | 0.0140 | 8 | 8 |
| tubercidin | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| toyocamycin | Homo sapiens (human) | IC50 | 1,616,107.6550 | 4 | 4 |
| nsc 65346 | Homo sapiens (human) | IC50 | 1,066,402.7350 | 4 | 4 |
| bromotubercidin | Homo sapiens (human) | IC50 | 4,163,612.5600 | 4 | 4 |
| 5-iodotubercidin | Homo sapiens (human) | IC50 | 9,670,462.6187 | 8 | 8 |
| 5-iodotubercidin | Homo sapiens (human) | Ki | 0.0265 | 5 | 5 |
| 5-chlorotubercidin | Homo sapiens (human) | IC50 | 2,387,652.6050 | 4 | 4 |
| 5'-deoxytoyocamycin | Homo sapiens (human) | IC50 | 1,076,163.5400 | 3 | 3 |
| clitocine | Homo sapiens (human) | IC50 | 26.0000 | 1 | 1 |
| clitocine | Homo sapiens (human) | Ki | 1.9333 | 3 | 3 |
| gp 1-515 | Homo sapiens (human) | IC50 | 0.0040 | 1 | 1 |
| gp 683 | Homo sapiens (human) | IC50 | 0.0005 | 5 | 5 |
| 5'-amino-5'-deoxyadenosine | Homo sapiens (human) | IC50 | 2.2233 | 3 | 3 |
Drugs with Activation Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| indole | Homo sapiens (human) | Kd | 3,000.0000 | 2 | 2 |
| fasudil | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| imatinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| triciribine phosphate | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| 2-phenylimidazole | Homo sapiens (human) | Kd | 3,000.0000 | 1 | 1 |
| picropodophyllin | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| gefitinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| lestaurtinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| perifosine | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| vatalanib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| ruboxistaurin | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| canertinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| cyc 202 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| enzastaurin | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| erlotinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| lapatinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| sorafenib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| s 1033 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| xl147 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| bms 387032 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| sf 2370 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| tandutinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| dasatinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| ha 1100 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| 7-epi-hydroxystaurosporine | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| zd 6474 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| imd 0354 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| sirolimus | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| alvocidib | Homo sapiens (human) | Kd | 2.4410 | 1 | 1 |
| bosutinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| orantinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| su 11248 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| palbociclib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| vx680 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| cyc 116 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| everolimus | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| ekb 569 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| axitinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| temsirolimus | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| on 01910 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| av 412 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| telatinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| y-39983 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| cp 547632 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| lenvatinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| pd 0325901 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| midostaurin | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| px-866 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| ripasudil | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| osi 930 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| scio-469 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| cp 724714 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| hmn-214 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| tivozanib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| hki 272 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| tofacitinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| cediranib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| masitinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| ly-2157299 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| pazopanib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| azd 6244 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| su 14813 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| bibw 2992 | Homo sapiens (human) | Kd | 3.4930 | 1 | 1 |
| binimetinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| sotrastaurin | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| aee 788 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| saracatinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| vx 702 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| crenolanib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| tg100-115 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| cc 401 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| bms 599626 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| exel-7647 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| volasertib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| azd 7762 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| regorafenib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| 6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| brivanib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| mp470 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| rgb 286638 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| np 031112 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| at 7519 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| bms-690514 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| bi 2536 | Homo sapiens (human) | Kd | 1.1630 | 1 | 1 |
| inno-406 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| kw 2449 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| danusertib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| abt 869 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| azd 8931 | Homo sapiens (human) | Kd | 1.4040 | 1 | 1 |
| arq 197 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| azd 1152 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| pf 00299804 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| ridaforolimus | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| 6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-n-(2,2-dimethylprpyl)-3-pyridinecarboxamide | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| cc-930 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| tak 285 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| idelalisib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| crizotinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| osi 906 | Homo sapiens (human) | Kd | 30.0000 | 1 | 2 |
| chir-265 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| motesanib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| fostamatinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| trametinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 2 |
| mln8054 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| pf-562,271 | Homo sapiens (human) | Kd | 30.0000 | 1 | 2 |
| jnj-26483327 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| ly2603618 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| tg100801 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| dactolisib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| bgt226 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| gsk 461364 | Homo sapiens (human) | Kd | 2.5070 | 1 | 1 |
| azd 1152-hqpa | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| enmd 2076 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| e 7050 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| tak-901 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| buparlisib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| azd 1480 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| azd8330 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| pha 848125 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| ro5126766 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| fedratinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| gsk690693 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| 14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| azd5438 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| pf 04217903 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| gdc 0941 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| icotinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| ph 797804 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| kx-01 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| mk 5108 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| cx 4945 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| cudc 101 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| arry-614 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| mln 8237 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| sgx 523 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| bms 754807 | Homo sapiens (human) | Kd | 30.0000 | 1 | 2 |
| bms 777607 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| sgi 1776 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| pci 32765 | Homo sapiens (human) | Kd | 30.0000 | 1 | 2 |
| ponatinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| amg 900 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| mk-1775 | Homo sapiens (human) | Kd | 0.0130 | 1 | 1 |
| AMG-208 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| quizartinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| at13148 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| tak 733 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| mk 2206 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| sns 314 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| lucitanib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| pf-04691502 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| dcc-2036 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| cabozantinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| ly2584702 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| incb-018424 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| poziotinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| entrectinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| pexidartinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| TAK-580 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| gsk 2126458 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| emd1214063 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| pf 3758309 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| gdc 0980 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| azd2014 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| (5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| plx4032 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| gsk 1363089 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| arry-334543 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| kin-193 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| mk 2461 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| bay 869766 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| as 703026 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| baricitinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| dabrafenib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| pki 587 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| n-(3-fluoro-4-((1-methyl-6-(1h-pyrazol-4-yl)-1h-indazol-5 yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| ribociclib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| mk-8033 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| pha 793887 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| sb 1518 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| abemaciclib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| mk-8776 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| gsk 1070916 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| jnj38877605 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| dinaciclib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| gilteritinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| alectinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| glpg0634 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| encorafenib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| bms-911543 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| gsk2141795 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| azd8186 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| byl719 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| cep-32496 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| rociletinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| ceritinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| azd1208 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| vx-509 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| volitinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| osimertinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| at 9283 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| otssp167 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| chir 258 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| osi 027 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| nintedanib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| bay 80-6946 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
Drugs with Other Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| adenosine | Homo sapiens (human) | ED50 | 10.0000 | 1 | 1 |
| 5-iodotubercidin | Homo sapiens (human) | ED50 | 0.0080 | 1 | 1 |
Fragment-based drug discovery.Journal of medicinal chemistry, , Jul-01, Volume: 47, Issue:14, 2004
Design of adenosine kinase inhibitors from the NMR-based screening of fragments.Journal of medicinal chemistry, , Dec-14, Volume: 43, Issue:25, 2000
South (S)- and North (N)-Methanocarba-7-Deazaadenosine Analogues as Inhibitors of Human Adenosine Kinase.Journal of medicinal chemistry, , 07-28, Volume: 59, Issue:14, 2016
Recent advances in the chemistry and biology of pyridopyrimidines.European journal of medicinal chemistry, , May-05, Volume: 95, 2015
Discovery and optimization of 2-aryl oxazolo-pyrimidines as adenosine kinase inhibitors using liquid phase parallel synthesis.Bioorganic & medicinal chemistry letters, , Apr-19, Volume: 14, Issue:8, 2004
Fragment-based drug discovery.Journal of medicinal chemistry, , Jul-01, Volume: 47, Issue:14, 2004
Pyridopyrimidine analogues as novel adenosine kinase inhibitors.Bioorganic & medicinal chemistry letters, , Aug-20, Volume: 11, Issue:16, 2001
Discovery of 4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, an orally active, non-nucleoside adenosine kinase inhibitor..Journal of medicinal chemistry, , Jun-21, Volume: 44, Issue:13, 2001
Design of adenosine kinase inhibitors from the NMR-based screening of fragments.Journal of medicinal chemistry, , Dec-14, Volume: 43, Issue:25, 2000
A TOPS-MODE approach to predict adenosine kinase inhibition.Bioorganic & medicinal chemistry letters, , Jun-21, Volume: 14, Issue:12, 2004
QSAR study on adenosine kinase inhibition of pyrrolo[2,3-d]pyrimidine nucleoside analogues using the hansch approach.Bioorganic & medicinal chemistry letters, , Mar-25, Volume: 12, Issue:6, 2002
Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition, and antiseizure activity of 5-iodotubercidin analogues.Journal of medicinal chemistry, , Jul-27, Volume: 43, Issue:15, 2000
A TOPS-MODE approach to predict adenosine kinase inhibition.Bioorganic & medicinal chemistry letters, , Jun-21, Volume: 14, Issue:12, 2004
QSAR study on adenosine kinase inhibition of pyrrolo[2,3-d]pyrimidine nucleoside analogues using the hansch approach.Bioorganic & medicinal chemistry letters, , Mar-25, Volume: 12, Issue:6, 2002
Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition, and antiseizure activity of 5-iodotubercidin analogues.Journal of medicinal chemistry, , Jul-27, Volume: 43, Issue:15, 2000
A TOPS-MODE approach to predict adenosine kinase inhibition.Bioorganic & medicinal chemistry letters, , Jun-21, Volume: 14, Issue:12, 2004
QSAR study on adenosine kinase inhibition of pyrrolo[2,3-d]pyrimidine nucleoside analogues using the hansch approach.Bioorganic & medicinal chemistry letters, , Mar-25, Volume: 12, Issue:6, 2002
Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition, and antiseizure activity of 5-iodotubercidin analogues.Journal of medicinal chemistry, , Jul-27, Volume: 43, Issue:15, 2000
Structure-Guided Drug Design of 6-Substituted Adenosine Analogues as Potent Inhibitors of Mycobacterium tuberculosis Adenosine Kinase.Journal of medicinal chemistry, , 05-09, Volume: 62, Issue:9, 2019
South (S)- and North (N)-Methanocarba-7-Deazaadenosine Analogues as Inhibitors of Human Adenosine Kinase.Journal of medicinal chemistry, , 07-28, Volume: 59, Issue:14, 2016
Focused screening to identify new adenosine kinase inhibitors.Bioorganic & medicinal chemistry, , 11-01, Volume: 24, Issue:21, 2016
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.Proceedings of the National Academy of Sciences of the United States of America, , Dec-18, Volume: 104, Issue:51, 2007
Adenosine kinase inhibitors. 5. Synthesis, enzyme inhibition, and analgesic activity of diaryl-erythro-furanosyltubercidin analogues.Journal of medicinal chemistry, , Oct-06, Volume: 48, Issue:20, 2005
A TOPS-MODE approach to predict adenosine kinase inhibition.Bioorganic & medicinal chemistry letters, , Jun-21, Volume: 14, Issue:12, 2004
Adenosine kinase inhibitors. 3. Synthesis, SAR, and antiinflammatory activity of a series of l-lyxofuranosyl nucleosides.Journal of medicinal chemistry, , Oct-23, Volume: 46, Issue:22, 2003
QSAR study on adenosine kinase inhibition of pyrrolo[2,3-d]pyrimidine nucleoside analogues using the hansch approach.Bioorganic & medicinal chemistry letters, , Mar-25, Volume: 12, Issue:6, 2002
Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition, and antiseizure activity of 5-iodotubercidin analogues.Journal of medicinal chemistry, , Jul-27, Volume: 43, Issue:15, 2000
New adenosine kinase inhibitors with oral antiinflammatory activity: synthesis and biological evaluation.Journal of medicinal chemistry, , Oct-29, Volume: 36, Issue:22, 1993
A TOPS-MODE approach to predict adenosine kinase inhibition.Bioorganic & medicinal chemistry letters, , Jun-21, Volume: 14, Issue:12, 2004
QSAR study on adenosine kinase inhibition of pyrrolo[2,3-d]pyrimidine nucleoside analogues using the hansch approach.Bioorganic & medicinal chemistry letters, , Mar-25, Volume: 12, Issue:6, 2002
Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition, and antiseizure activity of 5-iodotubercidin analogues.Journal of medicinal chemistry, , Jul-27, Volume: 43, Issue:15, 2000
QSAR study on adenosine kinase inhibition of pyrrolo[2,3-d]pyrimidine nucleoside analogues using the hansch approach.Bioorganic & medicinal chemistry letters, , Mar-25, Volume: 12, Issue:6, 2002
Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition, and antiseizure activity of 5-iodotubercidin analogues.Journal of medicinal chemistry, , Jul-27, Volume: 43, Issue:15, 2000
Discovery of 4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, an orally active, non-nucleoside adenosine kinase inhibitor..Journal of medicinal chemistry, , Jun-21, Volume: 44, Issue:13, 2001
Synthesis, intramolecular hydrogen bonding, and biochemical studies of clitocine, a naturally occurring exocyclic amino nucleoside.Journal of medicinal chemistry, , Volume: 31, Issue:4, 1988
South (S)- and North (N)-Methanocarba-7-Deazaadenosine Analogues as Inhibitors of Human Adenosine Kinase.Journal of medicinal chemistry, , 07-28, Volume: 59, Issue:14, 2016
Adenosine kinase inhibitors. 4. 6,8-Disubstituted purine nucleoside derivatives. Synthesis, conformation, and enzyme inhibition.Journal of medicinal chemistry, , May-05, Volume: 48, Issue:9, 2005
Adenosine kinase inhibitors. 6. Synthesis, water solubility, and antinociceptive activity of 5-phenyl-7-(5-deoxy-beta-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidines substituted at C4 with glycinamides and related compounds.Journal of medicinal chemistry, , Dec-01, Volume: 48, Issue:24, 2005
Adenosine kinase inhibitors. 5. Synthesis, enzyme inhibition, and analgesic activity of diaryl-erythro-furanosyltubercidin analogues.Journal of medicinal chemistry, , Oct-06, Volume: 48, Issue:20, 2005
Adenosine kinase inhibitors. 2. Synthesis, enzyme inhibition, and antiseizure activity of diaryltubercidin analogues.Journal of medicinal chemistry, , Jul-27, Volume: 43, Issue:15, 2000
Adenosine kinase inhibitors. 4. 6,8-Disubstituted purine nucleoside derivatives. Synthesis, conformation, and enzyme inhibition.Journal of medicinal chemistry, , May-05, Volume: 48, Issue:9, 2005
Discovery of 4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, an orally active, non-nucleoside adenosine kinase inhibitor..Journal of medicinal chemistry, , Jun-21, Volume: 44, Issue:13, 2001
Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition, and antiseizure activity of 5-iodotubercidin analogues.Journal of medicinal chemistry, , Jul-27, Volume: 43, Issue:15, 2000
Enables
This protein enables 5 target(s):
| Target | Category | Definition |
|---|
| RNA binding | molecular function | Binding to an RNA molecule or a portion thereof. [GOC:jl, GOC:mah] |
| deoxyadenosine kinase activity | molecular function | Catalysis of the reaction: 2'-deoxyadenosine + ATP = ADP + dAMP + 2 H+. [EC:2.7.1.76, RHEA:23452] |
| ATP binding | molecular function | Binding to ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator. [ISBN:0198506732] |
| metal ion binding | molecular function | Binding to a metal ion. [GOC:ai] |
| adenosine kinase activity | molecular function | Catalysis of the reaction: ATP + adenosine = ADP + AMP. [EC:2.7.1.20, PMID:11223943] |
Located In
This protein is located in 3 target(s):
| Target | Category | Definition |
|---|
| nucleoplasm | cellular component | That part of the nuclear content other than the chromosomes or the nucleolus. [GOC:ma, ISBN:0124325653] |
| cytosol | cellular component | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. [GOC:hjd, GOC:jl] |
| plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
Active In
This protein is active in 2 target(s):
| Target | Category | Definition |
|---|
| nucleus | cellular component | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. [GOC:go_curators] |
| cytosol | cellular component | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. [GOC:hjd, GOC:jl] |
Involved In
This protein is involved in 7 target(s):
| Target | Category | Definition |
|---|
| purine ribonucleoside salvage | biological process | Any process which produces a purine nucleoside from derivatives of it, without de novo synthesis. [GOC:jl] |
| dATP biosynthetic process | biological process | The chemical reactions and pathways resulting in the formation of dATP, deoxyadenosine triphosphate (2'-deoxyadenosine 5'-triphosphate). [ISBN:0198506732] |
| ribonucleoside monophosphate biosynthetic process | biological process | The chemical reactions and pathways resulting in the formation of a ribonucleoside monophosphate, a compound consisting of a nucleobase linked to a ribose sugar esterified with phosphate on the sugar. [GOC:go_curators, ISBN:0198506732] |
| GMP salvage | biological process | Any process which produces guanosine monophosphate from derivatives of it, without de novo synthesis. [GOC:mah] |
| AMP salvage | biological process | The chemical reactions and pathways resulting in the formation of adenosine monophosphate (AMP) from derivatives of it (either adenine, ADP or adenosine 3',5'-bisphosphate) without de novo synthesis. [GOC:ecd, GOC:jl, PMID:8917457, PMID:9864350] |
| dAMP salvage | biological process | Any process which produces a dAMP from derivatives of it, without de novo synthesis. [PMID:21829339, PMID:6605343] |
| purine nucleobase metabolic process | biological process | The chemical reactions and pathways involving purine nucleobases, one of the two classes of nitrogen-containing ring compounds found in DNA and RNA, which include adenine and guanine. [GOC:go_curators] |